Stefan Bulatovic, NP
Nurse Practitioner · Stockton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 5 years
- Graduated 2021
Offices
1 location · Mindful Health Solutions A Professional Medical Corporation · 55 clinicians in this group
Looking this up.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Stefan Bulatovic’s office at (844) 867-8444 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Medicaid work
$187,597 in 2024
Medicaid paid $187,597 for 1,349 billed services this clinician did in 2024, up to 105 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 1,040 | $160,910 |
| Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | 82 | $11,966 |
| Return visit (30+ min) | 81 | $8,809 |
| Annual depression screening, 5 to 15 minutes | 115 | $5,097 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 31 | $815 |
| 2024 | 1,349 | 5 | 105 | $187,597 |
| 2023 | 1,333 | 4 | 104 | $175,573 |
| 2022 | 443 | 2 | 94 | $66,782 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 1,107 | $167,943 |
| Annual depression screening, 5 to 15 minutes | 112 | $4,884 |
| Annual alcohol misuse screening, 5 to 15 minutes | 62 | $2,747 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 52 | $0 |
2022
| Long return visit (40+ min) | 429 | $66,782 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 14 | $0 |
Drugs they prescribed that Part D paid
$111,895
Pharmacies billed $111,895 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,168) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,085 generic and 83 brand-name prescriptions · $111,895 in drug cost · 59 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Invega Sustenna | 18 | $55,681 | $3,093 |
| Vraylar | 11 | $15,517 | $1,411 |
| Fetzima | 20 | $11,787 | $589 |
| Aripiprazole | 44 | $2,828 | $64 |
| Olanzapine | 105 | $2,711 | $26 |
See all 32 drugs
| Invega Sustenna | 18 | $55,681 | $3,093 |
| Vraylar | 11 | $15,517 | $1,411 |
| Fetzima | 20 | $11,787 | $589 |
| Aripiprazole | 44 | $2,828 | $64 |
| Olanzapine | 105 | $2,711 | $26 |
| Clozapine | 25 | $1,980 | $79 |
| Divalproex | 43 | $1,566 | $36 |
| Divalproex Sodium Er | 53 | $1,308 | $25 |
| Trazodone | 78 | $1,017 | $13 |
| Lamotrigine | 106 | $991 | $9 |
| Chlorpromazine | 17 | $900 | $53 |
| Atomoxetine | 26 | $860 | $33 |
| Escitalopram | 57 | $659 | $12 |
| Clonazepam | 56 | $654 | $12 |
| Fluoxetine | 44 | $617 | $14 |
| Guanfacine | 12 | $615 | $51 |
| Propranolol | 28 | $566 | $20 |
| Quetiapine | 86 | $508 | $6 |
| Risperidone | 29 | $461 | $16 |
| Lithium Carbonate | 45 | $424 | $9 |
| Haloperidol | 14 | $399 | $29 |
| Buspirone | 13 | $399 | $31 |
| Gabapentin | 28 | $390 | $14 |
| Quetiapine Fumarate Er | 13 | $289 | $22 |
| Citalopram Hbr | 22 | $287 | $13 |
| Clonidine | 30 | $235 | $8 |
| Duloxetine | 12 | $211 | $18 |
| Bupropion Xl | 20 | $138 | $7 |
| Lithium Carbonate Er | 17 | $104 | $6 |
| Hydroxyzine | 12 | $93 | $8 |
| Sertraline | 16 | $82 | $5 |
| Lorazepam | 14 | $46 | $3 |
Year by year
| 2024 | 1,168 | 46 | 0% (0) | 7% | $111,895 |
| 2023 | 676 | 40 | 0% (0) | 3% | $58,662 |
| 2022 | 576 | 35 | 0% (0) | 12% | $297,339 |
| 2021 | 67 | 14 | 0% (0) | None | $18,006 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Aripiprazole | 49 | $7,058 | $144 |
| Divalproex | 49 | $2,556 | $52 |
| Divalproex Sodium Er | 16 | $1,641 | $103 |
| Olanzapine | 38 | $1,133 | $30 |
| Atomoxetine | 16 | $935 | $58 |
| Risperidone | 59 | $876 | $15 |
| Trazodone | 55 | $685 | $12 |
| Quetiapine | 53 | $639 | $12 |
| Lamotrigine | 58 | $540 | $9 |
| Citalopram Hbr | 25 | $515 | $21 |
| Venlafaxine Hcl Er | 14 | $435 | $31 |
| Guanfacine | 12 | $402 | $34 |
| Haloperidol | 12 | $361 | $30 |
| Escitalopram | 29 | $328 | $11 |
| Buspirone | 12 | $282 | $24 |
| Gabapentin | 11 | $242 | $22 |
| Clonazepam | 27 | $185 | $7 |
| Lorazepam | 28 | $141 | $5 |
2022: 19 drugs
| Ingrezza | 11 | $78,116 | $7,101 |
| Invega Sustenna | 20 | $62,854 | $3,143 |
| Aripiprazole | 17 | $2,798 | $165 |
| Carbamazepine Er | 16 | $1,778 | $111 |
| Divalproex | 11 | $647 | $59 |
| Gabapentin | 42 | $565 | $13 |
| Quetiapine | 52 | $536 | $10 |
| Risperidone | 43 | $341 | $8 |
| Olanzapine | 23 | $324 | $14 |
| Trazodone | 38 | $310 | $8 |
| Buspirone | 14 | $272 | $19 |
| Fluoxetine | 36 | $225 | $6 |
| Benztropine Mesylate | 27 | $210 | $8 |
| Escitalopram | 13 | $102 | $8 |
| Clonazepam | 23 | $97 | $4 |
| Propranolol | 14 | $95 | $7 |
| Citalopram Hbr | 23 | $84 | $4 |
| Bupropion Xl | 12 | $75 | $6 |
| Sertraline | 16 | $63 | $4 |
Money from drug and device companies
$327 in 2025
| 2025 | 7 | 14 | None | $327 |
| 2024 | 4 | 9 | None | $221 |
| 2023 | 3 | 7 | None | $159 |
| 2022 | 4 | 6 | None | $124 |
| 2021 | 1 | 2 | None | $29 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Cobenfy | $82 | 2 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $77 | 4 payments
|
| Axsome Therapeutics | Auvelity | $58 | 2 payments
|
| Neurocrine BioSciences | Ingrezza | $35 | 2 payments
|
| Abbvie | Vraylar | $32 | 2 payments
|
| Janssen Pharmaceuticals | Spravato | $27 | 1 payment
|
See all 14 published payments
| Neurocrine BioSciences | Meals · 2025-12-13 | Ingrezza | $21 |
| Janssen Pharmaceuticals | Meals · 2025-12-05 | Spravato | $27 |
| Otsuka America Pharmaceutical | Meals · 2025-11-21 | Rexulti | $20 |
| Axsome Therapeutics | Meals · 2025-11-14 | Auvelity | $31 |
| Neurocrine BioSciences | Meals · 2025-10-17 | Ingrezza | $15 |
| Axsome Therapeutics | Meals · 2025-10-11 | Auvelity | $28 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-26 | Caplyta | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-06 | Cobenfy | $43 |
| Otsuka America Pharmaceutical | Meals · 2025-05-16 | Rexulti | $17 |
| Otsuka America Pharmaceutical | Meals · 2025-03-20 | Abilify Maintena | $27 |
| Abbvie | Meals · 2025-03-01 | Vraylar | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-07 | Cobenfy | $39 |
| Otsuka America Pharmaceutical | Meals · 2025-01-23 | Abilify Maintena | $14 |
| Abbvie | Meals · 2025-01-04 | Vraylar | $17 |
See earlier years (2024, 2023, 2022, 2021)
2024: $221
| Abbvie | Vraylar | $80 | 4 payments
|
| Otsuka America Pharmaceutical | Abilify Asimtufii | $79 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $37 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $25 | 1 payment
|
2023: $159
| Otsuka America Pharmaceutical | Rexulti | $72 | 3 payments
|
| Abbvie | Vraylar | $63 | 3 payments
|
| Iti | Caplyta | $24 | 1 payment
|
2022: $124
| Janssen Pharmaceuticals | Invega Sustenna | $45 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo | $37 | 2 payments
|
| Abbvie | Vraylar | $26 | 1 payment
|
| Alkermes | Aristada | $16 | 1 payment
|
2021: $29
| Otsuka America Pharmaceutical | Rexulti | $29 | 2 payments
|
Professional record
- NPI
- 1750053559
- Licence
- CA 95018067
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 3644 Wilson Ave, San Diego, CA, 92104
- NPI first listed
- 2021-09-30
- NPI last updated
- 2021-09-30
- NPI record certified
- 2021-09-30
This is when the NPI record was last certified, not a medical board exam.